Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel J Cook

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Mayo Clinic Proceedings|April 7, 2004
Aspergillus infection of implantable cardioverter-defibrillatorRachel J Cook, Thomas A Orszulak, Vuyisile T Nkomo, et al.
Seminars in Arthritis and Rheumatism|March 20, 2012
Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysisChristie M Bartels, Amy J H Kind, Carolyn T Thorpe, et al.
Hematology/Oncology and Stem Cell Therapy|March 6, 2019
Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 yearsCurtis Lachowiez, Rachel J Cook, Brandon Hayes-Lattin, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2022
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic MalignanciesAmer M Zeidan, Rachel J Cook, Rodolfo Bordoni, et al.
American Journal of Hematology|May 25, 2019
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapseRichard D Press, Garrett Eickelberg, Allison Froman, et al.
Cytotherapy|February 20, 2026
Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategiesYun Yu, Mikayla K Murphy, Virginia Tan, et al.
Cold Spring Harbor Molecular Case Studies|October 28, 2022
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemiaMara W Rosenberg, Samantha L Savage, Christopher A Eide, et al.
Cytotherapy|May 16, 2019
Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donorsLaura F Newell, Kelsea M Shoop, Rebekah J Knight, et al.
Blood Neoplasia|August 14, 2025
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemiaYesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, et al.
Blood Advances|November 28, 2022
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemiaCurtis A Lachowiez, Nicola Long, Jennifer Saultz, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Mayo Clinic Proceedings|April 7, 2004
Aspergillus infection of implantable cardioverter-defibrillatorRachel J Cook, Thomas A Orszulak, Vuyisile T Nkomo, et al.
Seminars in Arthritis and Rheumatism|March 20, 2012
Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysisChristie M Bartels, Amy J H Kind, Carolyn T Thorpe, et al.
Hematology/Oncology and Stem Cell Therapy|March 6, 2019
Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 yearsCurtis Lachowiez, Rachel J Cook, Brandon Hayes-Lattin, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2022
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic MalignanciesAmer M Zeidan, Rachel J Cook, Rodolfo Bordoni, et al.
American Journal of Hematology|May 25, 2019
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapseRichard D Press, Garrett Eickelberg, Allison Froman, et al.
Cytotherapy|February 20, 2026
Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategiesYun Yu, Mikayla K Murphy, Virginia Tan, et al.
Cold Spring Harbor Molecular Case Studies|October 28, 2022
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemiaMara W Rosenberg, Samantha L Savage, Christopher A Eide, et al.
Cytotherapy|May 16, 2019
Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donorsLaura F Newell, Kelsea M Shoop, Rebekah J Knight, et al.
Blood Neoplasia|August 14, 2025
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemiaYesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, et al.
Blood Advances|November 28, 2022
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemiaCurtis A Lachowiez, Nicola Long, Jennifer Saultz, et al.
Pageof 4